Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 208104, held by Lupin. Desoximetasone.
As of Nov 15, 2026, ANDA 208104 (Desoximetasone), held by Lupin, was first approved by FDA on Dec 1, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Desoximetasone ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 1, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · ointment;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
